1.
Targeted
Translational
RFA
for
Rare
Tumor
Subtypes
and
Exceptional
Responders
Request
for
Proposals
Deadline:
Monday,
June
1,
2015,
12
noon
Applications
are
requested
for
pilot
projects
that
seek
to
analyze
the
genomics,
transcriptomics,
with
or
without
additional
‘omics’
on
available
human
tissue
or
other
cellular
material
such
as
circulating
tumor
cells.
Material
must
be
already
available,
i.e.
banked
or
readily
available,
i.e.
for
open
or
soon
to
be
open
protocols
that
allow
access
to
tissue
or
blood
samples
for
pilot
studies.
Rare
tumor
subtypes
includes
rare
tumors
as
well
as
comparative
studies
of
known
molecular
subtypes
within
more
common
tumors.
Detailed
analysis
of
molecular
subtypes
within
common
tumors
is
considered
responsive.
In
2015
there
may
not
be
such
a
thing
as
a
'common'
tumor
given
all
the
heterogeneity
even
within
molecular
subtypes
of
common
tumors
not
to
mention
the
intra-­‐tumoral
heterogeneity.
For
exceptional
responders,
common
or
rare
tumors
are
included,
and
novel
or
conventional
agents
would
apply
as
long
as
the
novelty
and
significance
are
clear.
The
ideal
application
will
state
a
relevant
clinical
question
of
significance
to
the
understanding
of
the
tumor
classification,
molecular
drivers,
or
mediators
of
response
or
resistance.
Other
questions
of
interest
include
analysis
of
intra-­‐
or
inter-­‐tumor
heterogeneity
as
well
as
familial
associations
where
cases
cluster
within
families
particularly
within
the
FCCC-­‐Temple
catchment
area.
A
clear
delineation
of
the
comparisons
to
be
made
along
with
expected
impact
of
the
project
in
terms
of
publications,
funding,
and/or
new
clinical
protocols
that
take
the
knowledge
to
the
next
level
(e.g.
proposing
patient
selection
based
on
molecular
features
in
the
context
of
therapeutic
clinical
protocols).
A
goal
of
the
RFA
is
to
encourage
interdisciplinary
collaboration
as
well
as
application
of
the
latest
genomic
capabilities
available
including
those
that
are
internal
to
FCCC
(targeted
sequencing,
nanostring,
CTC
isolation
and
analysis
strategies).
Applications
may
introduce
novel
directions
to
existing
open
or
closed
clinical
studies
where
human
samples
with
clinical
outcomes
are
available.
Available
Support:
Funds
available
will
support
actual
use
of
technology
and
any
costs
associated
with
sample
identification
or
analysis.
Funds
for
this
RFA
may
not
be
used
for
salary
support.
The
typical
award
will
be
in
the
range
of
25-­‐50K
and
will
be
judged
on
expected
return-­‐on-­‐investment
(ROI)
for
a
given
request
and
scope
of
work
that
can
have
impact.
5-­‐6
awards
are
expected
to
be
made.
Application
Deadline:
June
1,
2015
at
12:00
pm.
Eligible
Principal
Investigators
must
be
a
member
of
one
of
the
five
CCSG
Research
Programs
of
the
Fox
Chase
Cancer
Center.

2. Submission
Guidelines:
Applications
need
an
abstract,
significance,
preliminary
information,
hypothesis,
goals/specific
aim/subaims,
feasibility
and
expected
impact
as
described
above.
Applications
must
not
exceed
five
(5)
pages,
including
the
above
sections
and
research
design,
but
excluding
references.
In
addition
provide
a
detailed
budget
page
(direct
costs
only,
no
salary
support
or
indirect
costs
allowed)
and
an
NIH
Biosketch
for
the
PI,
co-­‐PI(s)
and
Collaborators
that
includes
Other
Support
information.
Proposals
should
include
a
title
page
with
the
proposal
title,
PI,
Co-­‐PI(s)
(if
applicable),
and
Collaborators.
Review
Process
Applications
will
be
reviewed
by
the
end
of
June
with
awards
becoming
available
for
use
by
July
2015.
Please
direct
any
questions
to
Wafik
El-­‐Deiry
(wafik.eldeiry@fccc.edu).